World Pharma Pricing and Market Access Congress 2019
Last month, Directors Brett Gardiner and Rachel Howard attended the World Pharma Pricing and Market Access Congress in Amsterdam.
This two-day event was attended by over 600 delegates, including a number of payers from Europe, the US and Latin America, plus representatives from the industry and other market access organizations. In the morning plenary sessions, we heard a range of perspectives on value, demonstrating that “value is in the eye of the beholder”. A major focus was the new challenges facing Health Technology Assessment (HTA) organizations in view of the expanding pipeline of Advanced Therapy Medicinal Products (ATMPs) such as cell and gene therapy.
How we assessed the access potential of a new product in order to develop a successful launch strategy
Our client had two regimens in clinical development for the front-line treatment of an oncology condition using a breakthrough product; and planned to release outcomes data at key industry events throughout the year.
To ensure a fast and successful launch they wanted to develop key strategies to maximise acceptance and reimbursement of their product amongst HCPs and Payers.
How we facilitated mock negotiations with payers to improve the pricing strategy for a new biologic in Latin America
Our client wanted to understand how they should manage payer objections within the value proposition, clinical evidence and economic value of the product.
At offered prices, it would be cost-effective and have comparable / lower net budget impact than analogues. However, payers in Latin America were still expected to add further barriers or reject the reimbursement request. As a result our client wanted to understand how they should manage payer objections within the value proposition, clinical evidence and economic value of the product.
How we assessed payer perceptions of a new therapy for Atopic Dermatitis in emerging markets
Our client was developing a product for use in treating a number of indications including Atopic Dermatitis (AD); and wanted to understand how best to position this product in order to optimise pricing and market access.
Market research was required to understand payer perceptions of the AD market, and the pricing and reimbursement opportunities in emerging markets.
Research Partnership welcomes Marie Cawkwell
Research Partnership is pleased to welcome Marie Cawkwell as a Senior Analyst
Marie joins the company’s specialist market access team Access Partnership, which supports the world’s leading pharmaceutical, biotech and device manufacturers in market access, pricing, and reimbursement. She has accumulated over 5 years’ experience in healthcare research and consultancy since graduating from the University of Liverpool with an M.Res in Biomedical Science, and brings with her a wealth of skills and knowledge from her time working for a variety of market access consultancies.